Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged. The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.37. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 1.75. TheStreet Ratings group would like to highlight 3 stocks pushing the industry lower today: 3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.39 (-0.7%) to $51.96 on average volume Thus far, 955,421 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $51.49-$52.04 after having opened the day at $51.91 as compared to the previous trading day's close of $52.35. AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $64.6 billion and is part of the health care sector. The company has a P/E ratio of 10.4, below the S&P 500 P/E ratio of 17.7. Shares are up 9.4% year to date as of the close of trading on Wednesday. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AstraZeneca Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.